(4R)-3-Methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-L-prolinamide hydrochloride (1:1)
[CAS# 1948273-03-7]

Identification

• Classification: API >> Inhibitor drug
• Name: (4R)-3-Methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-L-prolinamide hydrochloride (1:1)
• Synonyms: E3 ligase Ligand 1
• Protein Sequence: XX
• Molecular Formula: C₂₃H₃₂N₄O₃S^.HCl
• Molecular Weight: 481.05
• CAS Registry Number: 1948273-03-7
• SMILES: CC1=C(SC=N1)C2=CC=C(C=C2)[C@H](C)NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)N)O.Cl

Safety Data

• Hazard Symbols: GHS07 Warning
• Hazard Statements: H302-H315-H319-H335
• Precautionary Statements: P261-P305+P351+P338

Discovory and Applicatios

(4R)-3-Methyl-L-valyl-4-hydroxy-N-[(1S)-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-L-prolinamide hydrochloride is a complex peptide derivative used in pharmaceutical research. The discovery of this compound dates back to the early 21st century, when there was a need to develop novel therapeutic agents that combined the properties of peptides with enhanced stability and activity. The researchers aimed to synthesize a molecule that retains the biological activity of peptides while overcoming common problems such as rapid degradation and low bioavailability. Its structure features a modified peptide chain of L-valine and proline analogs, containing a thiazole group attached to a benzene ring, which contributes to the biological activity of the compound. The molecule contains multiple chiral centers that affect its interaction with biological targets.

Due to its ability to interact with specific protein targets, this compound has been studied as a potential drug candidate. Its unique structure enables efficient binding to biomolecules, making it a promising lead in the field of drug discovery. The combination of the thiazole moiety and the peptide backbone makes it useful for designing drugs against various diseases, including infections and inflammatory diseases. Its structural features help improve pharmacokinetics and efficacy.

It is studied as a protease inhibitor, targeting enzymes that play a role in disease processes. By inhibiting these enzymes, the compound can modulate disease pathways and exert therapeutic effects in diseases such as cancer and viral infections. This compound can also affect metabolic pathways by inhibiting key enzymes, providing a tool for managing metabolic disorders or other related diseases.

The design of this molecule enables it to disrupt or modulate protein-protein interactions. This makes it a valuable tool for studying cellular processes and identifying new therapeutic targets. It can be used as a molecular probe to explore biological systems, helping to elucidate complex biochemical pathways and interactions.

Its modified peptide structure helps to study the bioavailability and stability of peptide drugs, addressing common challenges in peptide therapeutics. It is a model compound in mechanistic studies, providing insights into the behavior of similar molecules in biological systems.

The specific binding properties of this compound make it useful in the development of diagnostic tools to detect disease-related biomarkers. Its interaction with the target protein helps to detect and quantify disease markers. It can be used as an imaging agent to help visualize biological processes and disease states through techniques such as fluorescence or radioactive labeling.

References

2020. Lzk‑targeting degraders and methods of use. WO-2022051326-A1

2020. Bi-functional compounds and methods for targeted ubiquitination of androgen receptor. WO-2021236695-A1

2020. Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof. WO-2021226262-A1